Back

Salarius Pharmaceuticals Reports Business Highlights with Fourth Quarter and Full-Year 2020 Financial Results

Read More

Back

Salarius Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results

Read More

Back

Salarius Announces Closing of $23 Million Underwritten Public Offering of Common Stock Following Full Exercise of Over-Allotment Option

Read More

Back

Salarius Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

Read More

Back

Salarius Announces Proposed Public Offering of Common Stock

Read More